Performance was driven by a 29% unit growth in Oncology diagnostics, which management noted has been accelerating throughout the fiscal year. The Data business outperformed expectations with 69% growth in the quarter, fueled by a proprietary data set of over 450 petabytes of connected multimodal data. Management attributes their competitive moat to the 'flywheel' of using diagnostic data to train AI models, then delivering those insights back to physicians through 5,500 hospital connections. The Ins ...

Core Insights - Natera, Inc. is a leading company in the medical research industry, focusing on genetic testing and diagnostics, particularly in non-invasive prenatal testing and oncology diagnostics [1] - Cowen & Co. upgraded Natera's stock to a "Buy" rating, indicating a positive outlook for the company, with the stock price at approximately $230.75 [2] - Baird Financial Group Inc. significantly increased its investment in Natera by 277.8%, now holding 26,624 shares valued at around $4.5 million, reflecting strong institutional interest [2] - Other institutional investors, such as Northwestern Mutual Wealth Management Co. and Hilltop National Bank, have also increased their stakes in Natera, suggesting growing confidence in the company's potential [3] Stock Performance - Natera's current stock price is $229.97, showing a decrease of 1.36% or $3.16 [3] - The stock has traded between $229.32 and $234.58 on the day, with a one-year high of $246.90 and a low of $125.38 [3] - Natera has a market capitalization of approximately $31.74 billion and a trading volume of 237,608 shares, maintaining its significance in the market [3]